Beam Therapeutics (NASDAQ:BEAM) Earns Buy Rating from HC Wainwright
Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $80.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 202.80% from the stock’s previous close. Several […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $80.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 202.80% from the stock’s previous close. Several […]
